Gut microbiome directs the immune system to fight cancer
A worldwide collaboration has demonstrated a causal link between the gut microbiome and the immune system’s ability to fight cancer.
The advent of immune checkpoint inhibitors—which “release the brakes” of the body’s immune system to launch an efficient tumor attack—are a major breakthrough in cancer immunotherapy. However, these treatments don’t work for everybody and are often associated with significant side effects. The ability to stratify patients based on potential response to immune checkpoint inhibitors could therefore personalize cancer treatment. Efforts to understand the regulation of anti-tumor immunity (when the immune system fights a tumor) point to the importance of the gut microbiome. However, the underlying molecular mechanism(s) remain largely elusive.
Now, a worldwide collaboration involving more than 40 scientists and three hospitals led by researchers at Sanford Burnham Prebys has demonstrated a causal link between the gut microbiome and the immune system’s ability to fight cancer. Together, the researchers identified a cocktail of 11 bacterial strains that activated the immune system and slowed the growth of melanoma in mice. The study also points to the role of unfolded protein response (UPR), a cellular signaling pathway that maintains protein health (homeostasis). Reduced UPR was seen in melanoma patients who are responsive to immune checkpoint therapy, revealing potential markers for patient stratification. The study was published in Nature Communications.
“Immunotherapies have extended the lives of many cancer patients. However, the incredible effects we are seeing today are only the tip of the iceberg. By studying mechanisms of treatment response versus resistance, we can eventually expand the number of people who benefit from immunotherapy,” says Thomas Gajewski, M.D., Ph.D., the AbbVie Foundation Professor of Cancer Immunotherapy at the University of Chicago Medicine. “This study provides an important step toward this goal. The investigators have pinpointed the UPR as an important link between the gut microbiota and anti-tumor immunity. Given previous work indicating a causal role for the host microbiota in the efficacy of checkpoint blockade immunotherapy, this additional mechanistic insight should help select patients who will respond to treatment and also help to guide new therapeutic development.”
Although immune checkpoint therapies have significantly improved patient survival rates, metastatic melanoma remains the deadliest form of skin cancer, according to the American Cancer Society. Even when used as part of combination therapy, immune checkpoint inhibitors only benefit about half of patients, and these responses may involve autoimmune-related side effects, limited durability (the length of time a patient responds to treatment) and, at times, resistance to therapy. Accumulating evidence supports the role of the gut microbiome in effective immune therapy: Antibiotics and select probiotics reduce treatment efficacy, while certain bacterial strains enhance efficacy. This study sheds new light on these observations.
“Our study establishes a formal link between the microbiome and anti-tumor immunity and points to the role of the UPR in this process, answering a long-sought question for the field,” says Ze’ev Ronai, Ph.D., senior author of the study and a professor at Sanford Burnham Prebys’ NCI-designated Cancer Center. “These results also identify a collection of bacterial strains that could turn on anti-tumor immunity and biomarkers that could be used to stratify people with melanoma for treatment with select checkpoint inhibitors.”
“Boring” mice yield exciting results
Ronai has dedicated much of his lab’s efforts to understanding how cancer responds to stress and becomes treatment resistant. As part of this work, he and his team are studying a genetic mouse model that lacks the gene for RING finger protein 5 (RNF5), a ubiquitin ligase that helps remove inappropriately folded or damaged proteins. While these molecular traits are critical for the current study, the mice don’t show any outward signs of disease.
“We call them the ‘boring mice’ because they don’t have a notable phenotype,” says Ronai.
However, the RNF5-lacking mice were able to inhibit the growth of melanoma tumors, provided they had an intact immune system and gut microbiome. Treating these mice with a cocktail of antibiotics or housing the mice with their regular (wildtype) littermates abolished the anti-tumor immunity phenotype and consequently, tumor rejection—indicating the important role of the gut microbiome in anti-tumor immunity. Mapping the immune components engaged in the process revealed several immune system components, including Toll-like receptors and select dendritic cells, within the gut intestinal environment. Reduced UPR was commonly identified in immune and intestinal epithelial cells and was sufficient for immune cell activation. Reduced UPR signaling was also associated with the altered gut microbiomes seen in the mice.
Advanced bioinformatics techniques allowed the scientists to identify 11 bacterial strains that were enriched in the guts of the RNF5-lacking mice. Transferring these 11 bacterial strains to regular mice that lack intestinal bacteria (germ-free) induced anti-tumor immune response and slowed tumor growth.
To confirm that the results were relevant in human disease, the scientists obtained tissue samples from three cohorts of people with metastatic melanoma who subsequently received checkpoint inhibitor treatment. Indeed, reduced expression of UPR components (sXBP1, ATF4 and BiP) correlated with responsiveness to treatment, suggesting that there are potentially predictive biomarkers for the selection of patients who should receive immune checkpoint therapy.
Next, the scientists plan to determine what the bacteria are producing that slows tumor growth. These products, called metabolites, could then be tested to determine their ability to enhance anti-tumor immunity but also to define possible prebiotics that may be used to enrich their presence in the gut of melanoma patients.
“We believe this research applies to another fundamental question pertaining to the balance between anti-tumor immunity and autoimmunity,” says Ronai. “Because mice that lack RNF5 are also prone to developing gut inflammation—a side effect seen for certain immune checkpoint therapies—we can exploit this powerful model to study how we may tilt the balance between autoimmunity and anti-tumor immunity, which could help more people benefit from these remarkable therapies.”
Additional study authors include Yan Li, Ph.D., a postdoctoral researcher in the Ronai lab, who led the research in collaboration with Ronai lab members Yu Fujita, M.D., Ph.D., Yongmei Feng, Ph.D., Hyungsoo Kim, Ph.D., and Ali Khateb and Shiri K. Ashkenazi of the Technion, Israel Institute of Technology. Linda Bradley, Ph.D., and Roberto Tinoco, Ph.D., of Sanford Burnham Prebys provided immunology expertise. Scott Peterson, Ph.D., and Lisa Elmén of Sanford Burnham Prebys; and Amanda Raimer-Tait, Yibo Xian, Ph.D., Robert Schmaltz, and Rafael S. Muñoz of the University of Nebraska-Lincoln provided microbiota expertise. Key aspects of computational biology were provided by Tao Long, Ph.D., and Igor Segota, Ph.D., of Sanford Burnham Prebys, who established novel algorithms and a database for the current analysis in collaboration with Avinash Sahu and Eytan Ruppin, M.D., Ph.D., of the University of Maryland; Raphy Zarecki of Tel Aviv University; Tongwu Zhang, Ph.D., and Kevin Brown, Ph.D., of the National Cancer Institute (NCI); and Shibu Yooseph, Ph.D., of the University of Central Florida. Glenn Merlino, Ph.D., Kerrie Marie, Ph.D., Eva Guijarro Perez, Ph.D., and Chi-Ping Day, Ph.D., of the NCI; and Marcus Bosenberg, M.D., Ph.D., of Yale University provided expertise in mouse tumor models of melanoma. Members of the three medical centers that participated in this study include Dennie T. Frederick and Keith Flaherty, M.D., of Massachusetts General Hospital Cancer Center, Harvard Medical School; Emily Avitan-Hersh, M.D., Lihi Tzur, M.D., Shoshana Roizman, Ilanit Boyango, Ph.D., and Gil Bar-Sela, M.D., from Rambam Health Campus; and Mitchell P. Levesque, Ph.D., and Reinhard Dummer, M.D., of the University Hospital of Zurich. Randal J. Kaufman, Ph.D., and Bas Baaten, Ph.D., of Sanford Burnham Prebys; Colin R. Goding, Ph.D., of the Ludwig Institute for Cancer Research; and Miguel A. Tam of BioLegend also contributed to the study.
The study’s DOI is 10.1038/s41467-019-09525-y.
Research reported in this press release was supported by the National Institutes of Health (NIH) (P30CA030199, CA198103, DK103185, R35CA197465), Technion start-up funds, Melanoma Research Alliance (509524) and CDMRP (CA150892). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Melanoma is a deadly type of skin cancer. In 2019 it is estimated that nearly 100,000 new melanomas will be diagnosed, and approximately 7,000 people will die from the cancer, according to the American Cancer Society. Melanoma rates have been rising for the past 30 years, particularly in young women.